Glucon

Metformin Hydrochloride

Method of action: Drugs Used In Diabets, Hypoglycemic

Treatment option: Change Of Life, Obesity, Diabetes Mellitus, Type 2 Diabetes

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Glucon

Quick Facts	Description
Active Ingredient	Metformin Hydrochloride
Form	Oral Tablet (Standard and Extended-Release)
Pharmacological Class	Biguanide (Antihyperglycemic Agent)
General Purpose	Management of High Blood Sugar
Origin	Synthetic Compound

Glucon: Definition, Class, and Composition

Glucon is an oral prescription medicine whose sole active component is Metformin Hydrochloride (Metformin). This substance is classified as an antihyperglycemic agent and belongs specifically to the biguanide class of drugs. It is a synthetic compound, chemically synthesized rather than being naturally derived. Metformin is recognized as an effective agent in metabolic regulation.

The identity of Glucon is defined by its composition as a single-ingredient product, containing only Metformin Hydrochloride alongside essential pharmaceutical excipients. Its distinct classification as a biguanide has led to its broad acceptance in clinical practice. Metformin is considered an essential medicine for its efficacy in metabolic disorders. It serves as a first-line therapy for many individuals initiating the management of high blood sugar.

What Form of Medicine is Glucon?

Glucon is primarily manufactured as an oral tablet, meaning it must be swallowed for absorption through the digestive system. The tablet preparation is commonly available in both standard immediate-release and extended-release (XR) formulations. The extended-release form employs specialized coating technology to ensure the Metformin is released slowly over several hours, which can often simplify the administration schedule and improve patient tolerability.

As an oral medication, it supports straightforward, non-invasive long-term adherence to therapy. The tablet formulation is designed to provide consistent bioavailability for effective systemic action after oral administration.

What Is the General Purpose of Glucon?

The overarching purpose of Glucon is the management of elevated blood sugar, or hyperglycemia, predominantly seen in Type 2 diabetes. It functions to stabilize and help keep blood glucose levels within a safer, established range.

The therapeutic benefit is achieved through its combined actions: it reduces the amount of glucose that the liver produces, and it improves the body’s cells' response to its own natural insulin. These unique mechanisms, which directly mitigate core metabolic causes of high sugar, are the central actions that define the therapeutic utility of Glucon.

Regulatory References

What side effects are possible with Glucon?

Possible side effects and safety information

The official regulatory documentation for Glucon (Metformin Hydrochloride) classifies adverse reactions primarily by frequency and the System Organ Class (SOC) affected. The most frequently reported effects involve the Gastrointestinal system, while the most serious documented event is metabolic in nature.

Frequency Classification of Adverse Reactions

Frequency Classification	System-Organ Class (SOC)	Examples of Reactions
Very Common	Gastrointestinal Disorders	Diarrhea, Nausea, Vomiting, Abdominal Pain
Common	Metabolism and Nutrition	Vitamin B12 deficiency (with long-term use)
Very Rare	Metabolism and Nutrition	Lactic Acidosis (Serious)
Very Rare	Hepato-biliary Disorders	Hepatic function abnormalities, Hepatitis

Serious Adverse Reactions and Key Safety Constraints

The most serious reaction is lactic acidosis, which is classified as very rare but subject to specific warnings by regulatory authorities due to its potential severity. This risk is primarily linked to contraindicating conditions, particularly reduced kidney function. Use is restricted or contraindicated in individuals with severely impaired kidney function (e.g., eGFR below 30 mL/min/1.73 m^2) and in those with acute or chronic liver disease.

Common gastrointestinal adverse effects are typically reported to occur more frequently at the start of treatment and often subside with continued use. Conversely, a reduction in Vitamin B12 levels is associated with long-term exposure to the medicine, necessitating consideration for monitoring in such cases.

Overdose and Emergency Response

Overdose and When to Seek Help

Overdosage with Glucon is associated with a specific set of gastrointestinal symptoms. According to regulatory labeling, a suspected overdosage event requires immediate attention, even if symptoms have not yet appeared.

Documented Overdose Presentations

The following are the primary manifestations of overdosage with Glucon, as documented in official regulatory sources:

System Affected	Overdose Presentation/Symptom
Gastrointestinal	Nausea, vomiting, diarrhea, stomach relaxation

Emergency Action Required

Immediate medical help must be sought in all suspected cases of overdosage.

Official documents mandate that you immediately contact the Regional Poison Control Centre or your doctor, or go to the nearest hospital emergency department following a suspected overdosage. Seeking urgent medical assessment is the required course of action for managing a drug overdose event.

While some regulatory text suggests there is "NO DANGER OF OVERDOSE" when the product is used as directed for its primary purpose, explicit instructions for contacting emergency medical services are provided for any actual or suspected overdosage.

Therapeutic Uses of Glucon

Glucon is primarily used as a foundational approach to managing Type 2 Diabetes Mellitus to address chronic hyperglycemia, or symptoms related to systemic imbalance. This intervention contributes to the therapeutic benefit of stabilized blood glucose levels and is relevant for managing long-term glycemic control (A1C). The medication is commonly applied in contexts of metabolic risk reduction, notably in individuals with prediabetes, and provides supportive relief for conditions where functional stability becomes affected, such as Polycystic Ovary Syndrome (PCOS).

Quick Fact: Relief for Elevated Blood Sugar

The clinical situations where Glucon is relevant include Type 2 Diabetes Mellitus, prediabetes, and specific metabolic aspects of PCOS and Gestational Diabetes (GDM). Glucon plays a role in managing essential metabolic support across various patient groups, including adults, children and adolescents (age 10+), and women with GDM. The consistent use of the medication is relevant for managing health factors associated with diabetes and is commonly used to help with health factors related to circulatory function.

“This medication is a standard initial approach to supporting the body’s management of chronic, elevated blood sugar.”

Eligibility and Restrictions for Use

Who Can and Cannot Use Glucon (Metformin)

Official regulatory guidelines define the population eligibility for Glucon based primarily on physiological risk factors and age. Use is allowed for Adults and Children aged 10 years and older with Type 2 Diabetes Mellitus, provided their kidney function is adequate.

Contraindications and Restrictions

Absolute Contraindications (Must Not Use):

Severe Renal Impairment: The drug is strictly prohibited if the estimated glomerular filtration rate (eGFR is below 30 mL/min/1.73 m^2).
Metabolic Acidosis: Any form, including Diabetic Ketoacidosis (DKA).
Hypersensitivity: Known allergy to Metformin or its components.
Acute Instability: Conditions causing tissue hypoxia, such as acute heart failure or respiratory failure.

Conditional Restrictions:

Moderate Renal Impairment: Initiation is not recommended if eGFR is between 30 and 45 mL/min/1.73 m^2.
Procedural Discontinuation: Glucon must be temporarily discontinued for procedures involving iodinated contrast or major surgery.
Pregnancy and Lactation: Use is not generally recommended or is restricted, as insulin is often preferred during pregnancy, and the drug is generally discouraged during breastfeeding.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The official regulatory documentation for Glucon (Metformin Hydrochloride) identifies specific interaction patterns primarily related to its elimination pathway and its effect on blood sugar.

Interaction Classifications

Interaction Entity	Classification and Effect
Iodinated Contrast Agents	Formally Contraindicated under certain conditions. Requires mandatory suspension before and for 48 hours after procedures.
Renal Transporter Inhibitors	Clinically Significant Pharmacokinetic Interaction. These agents (e.g., Cimetidine, Ranolazine, Dolutegravir) formally increase Metformin plasma concentration by inhibiting its elimination via renal OCT and MATE transporters.
Alcohol (Ethanol)	Substance Restriction. Acute or excessive intake significantly heightens the risk of lactic acidosis, especially in individuals with hepatic impairment.

Pharmacodynamic and Exposure Effects

Co-administration with agents that possess hyperglycemic activity (e.g., glucocorticoids, thiazide diuretics, thyroid products) is documented to counteract the blood sugar-lowering effect of Glucon, leading to a loss of glycemic control. Conversely, combining it with other antihyperglycemic agents can increase the risk of hypoglycemia. Furthermore, drugs such as Furosemide and Nifedipine are formally documented to increase Metformin's systemic exposure (Cmax and AUC) by affecting its absorption or clearance. Regulatory constraints dictate that the interaction with iodinated contrast agents is mandatory for attention in patients with potential renal impairment.

Mechanism of Action

The mechanism of action of Glucon is defined by its core metabolic influence, exerted through three primary, non-insulin-secretory pathways. Decreasing Liver Glucose ProductionThe drug acts in the liver to mildly inhibit the Mitochondrial Respiratory Chain Complex I. This interaction changes the cellular energy ratio, activating the metabolic sensor, AMPK, which subsequently downregulates key enzymes like Glucose-6-Phosphatase ( G6Pase). This cascade reduces the rate of endogenous glucose output into the bloodstream, particularly in the fasting state.Enhancing Peripheral Tissue SensitivityGlucon drives an increase in glucose uptake by peripheral muscle and fat cells. By enhancing insulin signaling pathways, the drug increases the responsiveness of these cells to the body's native insulin. This AMPK-mediated action facilitates the translocation of glucose transporters, resulting in enhanced glucose disposal by peripheral cells.Modulating Intestinal AbsorptionThe medication influences the gastrointestinal tract to mildly reduce the rate at which glucose is absorbed from digested food. This complementary action modulates the rate of postprandial glucose entry into the circulation, affecting the resulting plasma glucose concentration curve.

Dosage and Administration Information

Glucon (Metformin HCl) is administered exclusively via the oral route for long-term use as part of a therapeutic regimen. The medication is available as both immediate-release (IR) and extended-release (ER) oral tablets. The administration protocol is determined by the specific formulation used.

Administration Guidelines

Usage Component	Standard Protocol
Dosing Initiation & Titration	Treatment begins with a low starting dose (e.g., 500 mg IR twice daily or ER once daily). The dose is gradually adjusted (titrated) in incremental steps, typically weekly, until the established maintenance level is reached, not exceeding the maximum daily dose of 2550 mg for IR forms.
Timing & Frequency	IR tablets must be administered with meals, typically two or three times per day (divided doses). ER tablets are generally administered once daily with the evening meal. ER tablets must be swallowed whole to preserve their release mechanism.
Renal Function Constraint	The use of Glucon is strictly dependent on kidney function, assessed by eGFR. The medicine's initiation is not recommended if the eGFR is between 30 and 45 mL/min/1.73 m^2, and use is contraindicated below 30 mL/min/1.73 m^2.
Procedural Use Restriction	The treatment must be temporarily discontinued at the time of, or prior to, certain iodinated contrast imaging procedures. Renal function must be assessed before starting and monitored periodically during the course of use.

This regimented administration protocol ensures the consistent long-term use of the medication. The age-specific rules permit use for pediatric patients age 10 and older, following specific lower starting and maximum doses.

Recent Clinical Evidence

Research evidence / Overview of studies for Glucon (Metformin)

Evidence for Use in Type 2 Diabetes Mellitus (T2DM)

The evidence base for Glucon (Metformin) was evaluated in research exploring high blood sugar associated with Type 2 Diabetes Mellitus (T2DM). Researchers utilized large-scale Randomized Controlled Trials (RCTs) and comprehensive longitudinal observational studies that monitored individuals for many years. These studies were used in research exploring how outcomes related to blood sugar markers evolved.

Research examined how Metformin use related to changes in long-term glycemic markers, such as Glycated Hemoglobin (A1C) and Fasting Plasma Glucose (FPG). Findings describe patterns observed in the measured levels of these markers in the adult population studied. The evidence for adults is extensive, but studies examining the outcomes in children and adolescents (age 10+) are still emerging.

Evidence for Metabolic Risk Reduction in Prediabetes

Metformin was applied in individuals at high metabolic risk in landmark, multi-year Randomized Controlled Trials (RCTs). The main focus of these trials was monitoring the rate at which participants met the diagnostic criteria for T2DM (the conversion endpoint). Key intervention trials reported measurements of the frequency of participants meeting the criteria for a T2DM diagnosis in the observed groups.

What remains uncertain is the degree to which these observed patterns persist over the very long term after the medication is discontinued. Results apply only to the specific high-risk populations studied, as follow-up durations were limited in the initial intervention phase.

Evidence in Special Populations, Including Pregnancy

Specific research has explored Metformin in special populations, including studies in children and adolescents and in pregnant women diagnosed with Gestational Diabetes Mellitus (GDM). For GDM, the evidence is derived from RCTs conducted during pregnancy that monitored maternal blood sugar levels and examined specific neonatal outcomes.

What Is Still Uncertain About Glucon

Long-term effects are not fully established for all outcomes. For the GDM population, long-term effects on the metabolic health of the offspring are not fully established and remain a key area of inquiry, as data are still emerging. Furthermore, significant study heterogeneity and modest sample sizes in certain subgroups mean that evidence quality varies across studies.

Key Studies & References

Frequently Asked Questions (FAQ)

Common questions about Glucon (FAQ)

Q: What should I do if I miss a dose of Glucon?

Official patient information states that if a dose is missed, taking it as soon as it is remembered is generally advised. However, if it is almost time for the next scheduled dose, the recommended instruction is to skip the missed dose and resume the regular schedule. The recommended practice is to avoid taking a double dose to compensate for the missed one.

Q: How long does it take for Glucon to start working after I take the first pill?

Regulatory information indicates that after taking an immediate-release tablet, the medicine typically reaches its maximum level in the bloodstream within about 2.5 hours. Consistent therapeutic levels are generally reached within one to two days of starting a regular dosing schedule.

Q: Does Glucon cause weight loss or weight gain?

Label information indicates that patients in clinical trials experienced a stability in or a reduction of body weight compared to those who received a placebo. The medicine is approved for the management of high blood sugar and is not specifically indicated for weight loss.

Q: How does Glucon actually lower blood sugar?

Regulatory documents describe the mechanism of action as working in three primary ways to help lower blood sugar. These include decreasing the amount of glucose (sugar) produced by the liver, reducing the absorption of glucose from the intestines, and increasing the body’s sensitivity to its own insulin.

Q: Why do I have to stop taking Glucon before a medical imaging test?

Official guidance advises that the medicine is temporarily stopped around the time of an imaging procedure that uses an iodinated contrast agent (a type of dye). This is due to regulatory warnings that the combination may increase the risk of a rare but serious metabolic condition called lactic acidosis.

Q: What are the differences between the immediate-release (IR) and extended-release (ER) forms?

Regulatory documents distinguish the two forms based on their administration and release profiles. Immediate-release ( IR) tablets are typically taken two or three times a day with meals. Extended-release ( ER) tablets are generally taken once daily with the evening meal and are intended to be swallowed whole to ensure the medicine is released slowly over an extended period.

How should Glucon be stored and disposed of?

Storage and Disposal Requirements for Glucon (Metformin Hydrochloride)

The official labeling for Glucon oral tablets specifies mandatory storage conditions to ensure product stability.

Storage Conditions

Requirement	Condition
Temperature	Store at Controlled Room Temperature (20°C to 25°C or 68°F to 77°F).
Protection	The tablets must be protected from moisture, humidity, and direct light. Do not freeze or expose to excessive heat.
Container	Keep the medicine in a closed container, preferably the original packaging.
Child Safety	Must be kept out of the sight and reach of children.

Disposal

Any unused or expired Glucon must be disposed of in accordance with local requirements. Do not throw outdated medicine into household trash or wastewater. Patients should consult a healthcare professional or pharmacist for guidance on local drug take-back programs.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Malaysia

A-Z Index:

A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z